HC Wainwright & Co. maintains $12.00 share target for Protalix BioTherapeutics
HC Wainwright & Co. maintained a $12.00-per-share price target for Protalix BioTherapeutics, per Benzinga ratings actions.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.